TITLE: Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study JOURNAL: Diabetes Research & Clinical Practice TYPE of PATIENTS: T2DM not controlled with Metformin + Glimepiride + DPP4-i NUMBER of PATIENTS: 360 patients ... Empagliflozin = 176 receiving , Dapagliflozin = 174 KEY RESULTS : Significantly more (p=0.021) pts.
on Empa (18.8%) reached the target HbA1c of <6.5% than those on Dapa (9.8%) Significantly more (p=0.036) pts. on Empa (35.2%) reached the target HbA1c of <7% than those on Dapa (24.7%) HbA1c reduction was significantly greater (p<0.001) with Empa (-1.6%) than with Dapa (-1.2%) FBG reduction was significantly greater (p=0.011) with Empa (-65 mg%) than with Dapa (-53 mg%) SIGNIFICANCE : The study adds to the conclusion that…
